Clinical Trial

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Study terminated due to various reasons impacting the feasibility of future clinical development
Summary
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Protocol Amendment History 4 changes
critical Trial terminated 2026-08-07
critical Trial terminated: Study terminated due to various reasons impacting the feasibility of future clinical development 2026-08-07
notable Primary completion moved earlier: 2025-12 -> 2025-01-01 2026-08-07
minor Completion moved earlier: 2025-12 -> 2025-01-01 2026-08-07
Trial Details
NCT Number NCT05226507
Lead Sponsor Nuvectis Pharma, Inc.
Collaborators: Gynecologic Oncology Group Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Conditions Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Enrollment 45 participants
Start Date 2021-12-31
Primary Completion 2025-01-01 (estimated)
Study Completion 2025-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06